World's Best Scientists 2026 revealed!
Richard N. Fedorak

Richard N. Fedorak

D-Index & Metrics

Medicine

D-Index
99
Citations
46083
World Ranking
8464
National Ranking
328

Richard N. Fedorak publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Richard N. Fedorak sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 600 publications — 72nd percentile

72% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Richard N. Fedorak D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Richard N. Fedorak sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 99 D-Index — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2011 - Fellow of the Royal Society of Canada Academy of Science

Overview

Richard N. Fedorak is affiliated with the University of Alberta in Canada. Their research primarily centers on the field of medicine, with notable contributions in several specialized subfields including epidemiology, genetics, health information management, surgery, and artificial intelligence.

The scientist's main topics of work span a range of areas related to gastrointestinal and healthcare technologies. These topics include:

  • Inflammatory Bowel Disease
  • Microscopic Colitis
  • Eosinophilic Esophagitis
  • Electronic Health Records Systems
  • Artificial Intelligence in Healthcare
  • Machine Learning in Healthcare
  • Biosimilars and Bioanalytical Methods

Frequent co-authors collaborating with Richard N. Fedorak comprise:

  • Reed T. Sutton
  • Karen I. Kroeker
  • Ellina Lytvyak
  • Levinus A. Dieleman
  • Farhad Peerani

Publication venues frequently featuring their work include:

  • Journal of the Canadian Association of Gastroenterology
  • npj Digital Medicine
  • Inflammatory Bowel Diseases
  • Digestive Diseases and Sciences
  • Crohn s & Colitis 360

Recent papers authored or co-authored by Richard N. Fedorak cover topics from clinical decision support systems to trends in surgical incidence and management of inflammatory bowel diseases. Notable recent publications include:

  • "An overview of clinical decision support systems: benefits, risks, and strategies for success" (2020), published in npj Digital Medicine
  • "Incidence Rates for Surgery in Crohn's Disease Have Decreased: A Population-based Time-trend Analysis" (2020), published in Inflammatory Bowel Diseases
  • "Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease" (2020), published in Digestive Diseases and Sciences
  • "Management of Inflammatory Bowel Disease Patients With Clinical Care Pathways Reduces Emergency Department Utilization" (2020), published in Crohn s & Colitis 360
  • "A162 OBESITY IS A RISK FACTOR FOR THE DEVELOPMENT OF THE EXTRAINTESTINAL MANIFESTATIONS IN ULCERATIVE COLITIS, BUT NOT IN CROHN'S DISEASE" (2021), published in Journal of the Canadian Association of Gastroenterology

Richard N. Fedorak was awarded the designation of Fellow of the Royal Society of Canada in 2011 within the Academy of Science.

Best Publications

  • Infliximab Maintenance Therapy for Fistulizing Crohn's Disease

    Bruce E. Sands;Frank H. Anderson;Charles N. Bernstein;William Y. Chey

  • Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

    William J. Sandborn;Brian G. Feagan;Paul Rutgeerts;Stephen Hanauer

  • Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial

    Stephen B. Hanauer;William J. Sandborn;Paul Rutgeerts;Richard N. Fedorak

  • An overview of clinical decision support systems: benefits, risks, and strategies for success.

    Reed T. Sutton;David Pincock;Daniel C. Baumgart;Daniel C. Sadowski

  • Adalimumab for Maintenance Treatment of Crohn's Disease: Results of the CLASSIC II Trial

    William J Sandborn;Stephen B Hanauer;Paul J Rutgeerts;Richard N Fedorak

  • Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.

    Brian G Feagan;Gordon R Greenberg;Gary Wild;Richard N Fedorak

  • Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice.

    Karen L. Madsen;Jason S. Doyle;Laurence D. Jewell;Michele M. Tavernini

  • Methotrexate for the Treatment of Crohn's Disease

    B G Feagan;J Rochon;R N Fedorak;E J Irvine

  • VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis

    Rodrigo Bibiloni;Richard N Fedorak;Gerald W Tannock;Karen L Madsen

  • A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators.

    B G Feagan;R N Fedorak;E J Irvine;G Wild

  • The epidemiology of inflammatory bowel disease in Canada: a population-based study.

    Charles N Bernstein;Andre Wajda;Lawrence W Svenson;Adrian MacKenzie

  • Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

    Walter Reinisch;William J Sandborn;Daniel W Hommes;Geert D'Haens

  • A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

    Stefan Schreiber;Paul Rutgeerts;Richard N. Fedorak;Munaa Khaliq–Kareemi

  • Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial

    Stephan R. Targan;Brian G. Feagan;Richard N. Fedorak;Bret A. Lashner

  • A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.

    William J. Sandborn;Brian G. Feagan;Richard N. Fedorak;Ellen Scherl

  • Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease

    Richard N. Fedorak;Alfred Gangl;Charles O. Elson;Paul Rutgeerts

  • Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease

    E. J. Irvine;B. Feagan;J. Rochon;A. Archambault

  • Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group.

    S.J.H. van Deventer;C.O. Elson;R.N. Fedorak

  • The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): Endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting.

    Alan Barkun;Sandrine Sabbah;Robert Enns;David Armstrong

  • World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011.

    Francisco Guarner;Aamir G. Khan;James Garisch;Rami Eliakim

Frequent Co-Authors

Brian G. Feagan
Brian G. Feagan University of Western Ontario
Remo Panaccione
Remo Panaccione University of Calgary
William J. Sandborn
William J. Sandborn University of California, San Diego
Stefan Schreiber
Stefan Schreiber Kiel University
Gilaad G. Kaplan
Gilaad G. Kaplan University of Calgary
Subrata Ghosh
Subrata Ghosh University College Cork
Stephen B. Hanauer
Stephen B. Hanauer Northwestern University
Jean-Frederic Colombel
Jean-Frederic Colombel Icahn School of Medicine at Mount Sinai

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical career in the US doesn’t always follow a single path. For those seeking different entry points or advancement opportunities in healthcare, there are several flexible online degree options tailored to various needs.

Registered Nurses can take advantage of online rn to bsn programs without clinical requirements. These programs allow working professionals to further their education on their own schedule and without the need for in-person practice hours.

Aspiring leaders and practitioners interested in a Doctor of Nursing Practice (DNP) can consider dnp online programs for a flexible format. Additionally, students looking to accelerate their study can choose from the dnp program without clinical hours—ideal for those wanting a streamlined approach to advanced roles.

Entry-level positions are also accessible, thanks to options like the lpn program. Fast-track online LPN programs make it possible to start your career in patient care quickly and affordably.

Best Scientists Citing Richard N. Fedorak

Trending Scientists

Recently Published Articles